Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions include references to specific results from the EARLY-AF trial, noting that patients who underwent cryoballoon ablation had lower rates of atrial fibrillation recurrence compared to those on antiarrhythmic drugs. Phrases like 'must consider risks and benefits' and 'important point' emphasize the thoughtful tone of the discussions while reflecting the weight of the findings on treatment decisions.
Overall, posts reflect a supportive sentiment regarding the benefits of cryoablation, but some express caution regarding individual patient considerations.
There is a high level of curiosity and relevance, as many discussions focus on recent studies and their implications for treating atrial fibrillation.
While many posts reference methods and outcomes, the depth of technical detail varies typically among participants.
Users perceive this publication as influential, with discussions highlighting the significant implications for patient care.
En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativamente menor de recurrencia con la ablación mediante criobalón con catéter comparado con la terapia con fármacos antiarrítmicos. DOI: 10.1056/NEJMoa2029980 https://t.co/ICkuvgOvNn
Impressive results presented at #AHA20 and simultaneously published in @NEJM! EARLY-AF is the largest trial comparing first-line ablation to anti-arrhythmic drugs for #AFib rhythm control. Congratulations to CCI Investigator @DrJasonAndrade & team! https://t.co/VBqHgVZzS4 #EPeeps https://t.co/puxTIZJK8u
A brief review from @ChrisCheungMD and myself on EARLY-AF now available through ACC. https://t.co/MKlki75Y2D https://t.co/Gr7sfYVYRu
@joshuarutlandmd @DrRoderickTung @DrBradleyKnight @narrowQRS @drpaulfriedman Here is our provincial pathway for sotalol initiation, titration, monitoring and discontinuation. Also published as the appendix in: - https://t.co/DUaZEijzi0 - https://t.co/5lxFere5ZI https://t.co/z4MqgbujZ1
Thanks to @msfhr for supporting new researchers in BC. The support provided from @msfhr enabled us to successfully complete CIRCA-DOSE, and set the path for us to successfully undertake EARLY-AF. https://t.co/jqQaRWHb42 https://t.co/rLpeg3qwvn https://t.co/aON10IVv0v
@AndreaRussoEP @DJ_Lakkireddy @utedrow @netta_doc @drrakeshg1 We didn’t discuss this on the panel - but in Canada we tend to do all AAD initiations as outpatients. https://t.co/5lxFere5ZI https://t.co/iMxkCz59QL
John Mandrola MD discusses early vs delayed AF ablation, highlighting a study that shows cryoablation significantly reduces persistent AF episodes compared to drug therapy. This video is aimed at healthcare…
This week, John Mandrola MD discusses three key aspects of the recent AF guidelines, emphasizing early rhythm-control therapy's potential to reduce cardiovascular risks. Join us for an in-depth analysis of the latest…
This podcast discusses recent trials including IRONMAN and ECMOCS, focusing on treatment options for atrial fibrillation. It reviews the effectiveness of cryoballoon ablation compared to antiarrhythmic drugs…
RT @simovicst: @Mel_Gunawardene @EHRAPresident @arbelo_e Cryo-FIRST https://t.co/QWPsZPuLPM STOP-AF First https://t.co/PyvAV9UKC0 EARLY-AF…
RT @simovicst: @Mel_Gunawardene @EHRAPresident @arbelo_e Cryo-FIRST https://t.co/QWPsZPuLPM STOP-AF First https://t.co/PyvAV9UKC0 EARLY-AF…
@Mel_Gunawardene @EHRAPresident @arbelo_e Cryo-FIRST https://t.co/QWPsZPuLPM STOP-AF First https://t.co/PyvAV9UKC0 EARLY-AF https://t.co/wS1R0V6j5X #EHRAchat https://t.co/QHIBi6YhEZ
RT @catweneboah: ⚡️Must consider risks and benefits of each individual patient when considering treatment options 6/6
RT @catweneboah: ⚡️Must consider risks and benefits of each individual patient when considering treatment options 6/6
RT @catweneboah: ⚡️Must consider risks and benefits of each individual patient when considering treatment options 6/6
⚡️Must consider risks and benefits of each individual patient when considering treatment options 6/6
RT @PriyaPBK: @JonKalmanEP @EHRAPresident @SteliosTzeis @EduardoSaad3 @Ed_Gerst EARLY-AF trial showed that patients treated with cryoballoo…
@JonKalmanEP @EHRAPresident @SteliosTzeis @EduardoSaad3 @Ed_Gerst EARLY-AF trial showed that patients treated with cryoballoon ablation had lower rate of AF recurrence and lower AF burden than patients treated with AADs https://t.co/bjZY8Kvbfb @DrJasonAndrade #EHRAchat https://t.co/02VsInuAYd
RT @EHRAPresident: #EHRAtopicweek First-line catheter ablation significantly reduced arrhythmia recurrence & arrhythmia burden. That led t…
RT @EHRAPresident: #EHRAtopicweek First-line catheter ablation significantly reduced arrhythmia recurrence & arrhythmia burden. That led t…
RT @EHRAPresident: #EHRAtopicweek First-line catheter ablation significantly reduced arrhythmia recurrence & arrhythmia burden. That led t…
RT @EHRAPresident: #EHRAtopicweek First-line catheter ablation significantly reduced arrhythmia recurrence & arrhythmia burden. That led t…
RT @EHRAPresident: #EHRAtopicweek First-line catheter ablation significantly reduced arrhythmia recurrence & arrhythmia burden. That led t…
RT @EHRAPresident: #EHRAtopicweek First-line catheter ablation significantly reduced arrhythmia recurrence & arrhythmia burden. That led t…
#EHRAtopicweek First-line catheter ablation significantly reduced arrhythmia recurrence & arrhythmia burden. That led to an improvement in QoL compared to med Tx, which led to a reduction in hospitalisation in the year following intervention. https://t.co/0tBQ0UL4dK
RT @DrJasonAndrade: While the publication of EARLY-AF / PROGRESSIVE-AF has been informative, there remains a key gap is translating that kn…
RT @DrJasonAndrade: While the publication of EARLY-AF / PROGRESSIVE-AF has been informative, there remains a key gap is translating that kn…
Full article open access #FOAMmed #NEJM: https://t.co/oqLi82NXdS
RT @DrJasonAndrade: While the publication of EARLY-AF / PROGRESSIVE-AF has been informative, there remains a key gap is translating that kn…
RT @DrJasonAndrade: While the publication of EARLY-AF / PROGRESSIVE-AF has been informative, there remains a key gap is translating that kn…
RT @DrJasonAndrade: While the publication of EARLY-AF / PROGRESSIVE-AF has been informative, there remains a key gap is translating that kn…
RT @DrJasonAndrade: While the publication of EARLY-AF / PROGRESSIVE-AF has been informative, there remains a key gap is translating that kn…
While the publication of EARLY-AF / PROGRESSIVE-AF has been informative, there remains a key gap is translating that knowledge to primary and specialist care. The care of electrophysiologists is too late in the treatment paradigm https://t.co/5lxFeqWv8a https://t.co/dO410eFTg3
RT @DrJasonAndrade: @drjohnm @bjcohenmd We had aggressive titrations protocols (see supplement) and gave the drug arm 90 days to optimise d…
RT @DrJasonAndrade: @drjohnm @bjcohenmd We had aggressive titrations protocols (see supplement) and gave the drug arm 90 days to optimise d…
@drjohnm @bjcohenmd We had aggressive titrations protocols (see supplement) and gave the drug arm 90 days to optimise dose before we counted failures. Despite multiple AADs and complete AF suppression on ILR the drug group still had 2x the recurrence and 3x progression. https://t.co/5lxFeqWv8a
https://t.co/rJB6oibmy9
RT @MichifumiTokuda: うちのボスとDr. Jason Andrade✨ Andrade先生は EARLY AF trial (N Engl J Med 2021)の1st Authorです。 Welcome to Japan！
RT @MichifumiTokuda: うちのボスとDr. Jason Andrade✨ Andrade先生は EARLY AF trial (N Engl J Med 2021)の1st Authorです。 Welcome to Japan！
うちのボスとDr. Jason Andrade✨ Andrade先生は EARLY AF trial (N Engl J Med 2021)の1st Authorです。 Welcome to Japan！
@Callme_DrNeil @netta_doc @drjohnm Presumably torsades? It’s data from a meta analysis of predominately placebo controlled trials. If you look in the appendix we saw polymorphic tachycardia in early-AF https://t.co/5lxFeqX2XI
RT @DrJasonAndrade: @Dominik_Linz @SZDiederichsen @ESC_Journals @EuropaceEiC Agree. This was a big reason why we only enrolled people wit…
@Dominik_Linz @SZDiederichsen @ESC_Journals @EuropaceEiC Agree. This was a big reason why we only enrolled people with “actionable” AF in the EARLY-AF trial. Enrolling first presentation would have limited power https://t.co/5lxFeqWv8a
https://t.co/CGYmD3UTmZ
3/x Methods -3y FU EARLY-AF (https://t.co/dxSES7xtZ2) -100% implanted ILR + daily homemonitoring transmissions
More recently, the trials spearheaded by @DrJasonAndrade, trialist extraordinaire, defined the role of catheter ablation in #AFib https://t.co/idJNqlN7oJ
RT @DrJasonAndrade: @AndreaRussoEP @DJ_Lakkireddy @utedrow @netta_doc @drrakeshg1 We didn’t discuss this on the panel - but in Canada we te…
RT @DrJasonAndrade: @AndreaRussoEP @DJ_Lakkireddy @utedrow @netta_doc @drrakeshg1 We didn’t discuss this on the panel - but in Canada we te…
RT @DrJasonAndrade: @AndreaRussoEP @DJ_Lakkireddy @utedrow @netta_doc @drrakeshg1 We didn’t discuss this on the panel - but in Canada we te…
RT @DrJasonAndrade: @AndreaRussoEP @DJ_Lakkireddy @utedrow @netta_doc @drrakeshg1 We didn’t discuss this on the panel - but in Canada we te…
RT @DrJasonAndrade: @AndreaRussoEP @DJ_Lakkireddy @utedrow @netta_doc @drrakeshg1 We didn’t discuss this on the panel - but in Canada we te…
@AndreaRussoEP @DJ_Lakkireddy @utedrow @netta_doc @drrakeshg1 We didn’t discuss this on the panel - but in Canada we tend to do all AAD initiations as outpatients. https://t.co/5lxFere5ZI https://t.co/iMxkCz59QL
RT @DrJasonAndrade: @peterkistler3 @PrashSanders @Ed_Gerst We reported all of those in early af - https://t.co/5lxFeqX2XI For circa-dose i…
@peterkistler3 @PrashSanders @Ed_Gerst We reported all of those in early af - https://t.co/5lxFeqX2XI For circa-dose it ended up being two papers - https://t.co/97N2Jp6MP6 - https://t.co/p6sX2R8pPT But we have gone back and related the QOL and HCU to burden (paper coming soon)
@mcfinlay @bogdienache @dredcronin @drjohnm I have thoughts about the operationalisation of a sham trial. @mcfinlay - are AADs being given to everyone? Or no one? @bogdienache - re trial endpoint- EARLY showed significant ⬆️ in QOL but only a trend to reduced HCU (underpowered at 300 patients). https://t.co/5lxFere5ZI
RT @DrJasonAndrade: In general we don’t admit for AAD initiation. If you look at the supplement for EARLY-AF we published the initiation, t…
The CANet-funded clinical trial, Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation, fulfils a critical need for minimally invasive cardiac procedures that improve patient outcomes. Read more below! https://t.co/fVYpQpN6TS
RT @DrJasonAndrade: @joshuarutlandmd @DrRoderickTung @DrBradleyKnight @narrowQRS @drpaulfriedman Here is our provincial pathway for sotalol…
RT @DrJasonAndrade: @joshuarutlandmd @DrRoderickTung @DrBradleyKnight @narrowQRS @drpaulfriedman Here is our provincial pathway for sotalol…
RT @DrJasonAndrade: @joshuarutlandmd @DrRoderickTung @DrBradleyKnight @narrowQRS @drpaulfriedman Here is our provincial pathway for sotalol…
RT @DrJasonAndrade: @joshuarutlandmd @DrRoderickTung @DrBradleyKnight @narrowQRS @drpaulfriedman Here is our provincial pathway for sotalol…
@joshuarutlandmd @DrRoderickTung @DrBradleyKnight @narrowQRS @drpaulfriedman Here is our provincial pathway for sotalol initiation, titration, monitoring and discontinuation. Also published as the appendix in: - https://t.co/DUaZEijzi0 - https://t.co/5lxFere5ZI https://t.co/z4MqgbujZ1
In general we don’t admit for AAD initiation. If you look at the supplement for EARLY-AF we published the initiation, titration, and monitoring protocols for flecainide, propafenone, sotalol, amiodarone, and dronedarone. https://t.co/5lxFere5ZI https://t.co/PewzjfWbVV
https://t.co/Ag7VGTT34H
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | ECR Journal https://t.co/XgVNMn0qjP
@ProfDConnelly @JonPicciniSr Agree with the how early is early issue. RCTs here to help! @DrJasonAndrade and the EARLY-AF investigators support the go early approach: https://t.co/ycxUSXNSwA
EARLY-AF Trial Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation https://t.co/2NV1DgpgPO https://t.co/Mm6YyjOmZx
RT @DrJasonAndrade: So absolute recurrence appears greater in EARLY-AF due to more intense monitoring. But the relative difference btw tr…
RT @DrJasonAndrade: So pleased to présent EARLY-AF this morning @AHAMeetings - Largest first line ablation study. - Continuous monitoring…
RT @DrJasonAndrade: I should follow that up by pointing out the central role @Ricky_Turgeon played in the analysis. Ans i should thank th…
I should follow that up by pointing out the central role @Ricky_Turgeon played in the analysis. Ans i should thank the co-Authors from EARLY-AF - https://t.co/rLpeg3qwvn STOP-AF first - https://t.co/gFSz01ny04 CRYO-first - https://t.co/uuXvzFENQh @ubcpharmacy
EARLY-AF: L'ablation précoce de FA paroxystique prévient mieux les récidives que les anti-arythmiques https://t.co/51iImBtO5N
RT @AmbrizMau: En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativam…
RT @AmbrizMau: En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativam…
RT @AmbrizMau: En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativam…
RT @AmbrizMau: En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativam…
RT @AmbrizMau: En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativam…
RT @AmbrizMau: En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativam…
RT @AmbrizMau: En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativam…
RT @AmbrizMau: En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativam…
En pacientes que recibieron terapia inicial para fibrilación auricular paroxística sintomática, hubo una tasa significativamente menor de recurrencia con la ablación mediante criobalón con catéter comparado con la terapia con fármacos antiarrítmicos. DOI: 10.1056/NEJMoa2029980 https://t.co/ICkuvgOvNn
RT @DrJasonAndrade: @djcantillonmd @omwazni @Dr_DanMD @AmitGoyalMD Important point. In EARLY-AF we saw malignant arrhythmias in the AAD gro…
RT @DrJasonAndrade: @CardioNerdsJC Our AAD titration protocols are available in the supplement of the main paper - https://t.co/rLpeg3qwvn…
RT @DrJasonAndrade: @CardioNerdsJC Our AAD titration protocols are available in the supplement of the main paper - https://t.co/rLpeg3qwvn…
@HafizaKMD @CardioNerdsJC We reported both the treatment related SAE (in the first tweet) and the broader any AE (9% ABL vs 16% AAD). https://t.co/rLpeg3qwvn
RT @DrJasonAndrade: So absolute recurrence appears greater in EARLY-AF due to more intense monitoring. But the relative difference btw tr…
RT @DrJasonAndrade: So absolute recurrence appears greater in EARLY-AF due to more intense monitoring. But the relative difference btw tr…
So absolute recurrence appears greater in EARLY-AF due to more intense monitoring. But the relative difference btw treatment groups (~0.5) is no different between STOP-AF and EARLY-AF. #cardsJC https://t.co/rLpeg3qwvn
@CardioNerdsJC Our AAD titration protocols are available in the supplement of the main paper - https://t.co/rLpeg3qwvn And the methods paper - https://t.co/DUaZEijzi0 The goal was to provide a practical resource for all treating clinicians.
RT @CardioNerdsJC: Different anti-arrhythmic algorithms were used for Early-AF (https://t.co/eDhJLV1Wxc) vs STOP-AF (https://t.co/QSvMu3…
RT @CardioNerdsJC: Different anti-arrhythmic algorithms were used for Early-AF (https://t.co/eDhJLV1Wxc) vs STOP-AF (https://t.co/QSvMu3…
@djcantillonmd @omwazni @Dr_DanMD @AmitGoyalMD Important point. In EARLY-AF we saw malignant arrhythmias in the AAD group despite careful titration protocols. https://t.co/rLpeg3qwvn https://t.co/S0V0kVTY3e
Different anti-arrhythmic algorithms were used for Early-AF (https://t.co/eDhJLV1Wxc) vs STOP-AF (https://t.co/QSvMu39p9o) ❓How can these differences impact the study? Do you think this impacted the study, and, if so, how? #CardsJC https://t.co/m4SXa0EqzG
RT @CardioNerdsJC: ❤️
❤️
@drjohnm @DhirajGuptaBHRS To be fair. I was asked to present on the role of AF burden as an efficacy parameter post AF ablation. It leaned heavily on CIRCA-DOSE and touched on EARLY-AF as both used ILRs. https://t.co/97N2JoODAY https://t.co/rLpeg3qwvn
Guidelines recommend a trial of one or more antiarrhythmic drugs before catheter ablation is considered in patients with atrial fibrillation. However, https://t.co/U0SbxCHGTp
Jason Andrade @VCHhealthcare discusses the lower rate of atrial fibrillation recurrence found with catheter cryoballoon ablation than with antiarrhythmic drug therapy #medicine https://t.co/jUYN7mbVwo https://t.co/LLmEC4CF0m
Nutshell #240: In patients with atrial fibrillation, catheter ablation led to 24.9% lower rate of atrial tachyarrhythmia recurrence and 3.3% lower rate of atrial fibrillation recurrence compared to antiarrhythmic drugs. @NEJM https://t.co/JYX9Oo82Q1
RT @ECG_Emily: And here are the studies I referred to during the presentation.... CIRCA-DOSE and EARLY-AF https://t.co/s7Ti8wXw2B @DrJasonA…
And here are the studies I referred to during the presentation.... CIRCA-DOSE and EARLY-AF https://t.co/s7Ti8wXw2B @DrJasonAndrade
@EJSMD @nmarrouche For early-AF we had a committee that had to approve cross-overs. Patients were only allowed to change treatment groups if they had already met primary endpoint on a therapeutic AAD dose. https://t.co/rLpeg3qwvn https://t.co/uyFzFaHTQX
https://t.co/p19brezr4U
(2/3) A study in the #NEJM recently found that, as compared to anti-arrhythmic drug therapy, catheter cryoablation significantly reduced atrial fibrillation recurrence. #biom4180 https://t.co/zlVyme7IF3
RT @DrJasonAndrade: Thanks to @msfhr for supporting new researchers in BC. The support provided from @msfhr enabled us to successfully co…
Thanks to @msfhr for supporting new researchers in BC. The support provided from @msfhr enabled us to successfully complete CIRCA-DOSE, and set the path for us to successfully undertake EARLY-AF. https://t.co/jqQaRWHb42 https://t.co/rLpeg3qwvn https://t.co/aON10IVv0v
CARDIOLOGIA-Andrade J.G. et al.-Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation-2021.- https://t.co/678KjtrxYm
Los pacientes con fibrilación auricular paroxística sintomática, tuvieron una tasa significativamente menor de recurrencia de la fibrilación auricular tratados con ablación con criobalón con catéter que con la terapia con fármacos antiarrítmicos. https://t.co/11qFKj8Djh
RT @RevistaMFSamfyc: Crioablación o terapia farmacológica en el tratamiento inicial de la fibrilación auricular https://t.co/TvxKVpQgES PMI…
Crioablación o terapia farmacológica en el tratamiento inicial de la fibrilación auricular https://t.co/TvxKVpQgES PMID 33197159
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM EARLY-AF https://t.co/Dsxcphw41g
42.9% recurrence at one year after PVI with cyro-ablation! Tough statistics to tell your patient. https://t.co/XIccR3OXsg
A quick chat with @CardiologyTalk on EARLY-AF. https://t.co/rLpeg3qwvn https://t.co/lsXdaINUPY
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/ORLnHgEcPL
RT @Saludteca: Crioablación o fármacos como tratamiento inicial de la fibrilación auricular (1.02.2021) https://t.co/auIAglnY7i resumen @fi…
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation @DrJasonAndrade @VCHhealthcare @ICMtl #AtrialFibrillation #Cardioloy #Research Link To FULL Video: https://t.co/73yU6k39CR https://t.co/fENrFIfFo7
RT @DrJasonAndrade: A brief review from @ChrisCheungMD and myself on EARLY-AF now available through ACC. https://t.co/MKlki75Y2D https://…
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/nAENvvsCYc
RT @DrJasonAndrade: A brief review from @ChrisCheungMD and myself on EARLY-AF now available through ACC. https://t.co/MKlki75Y2D
RT @DrJasonAndrade: A brief review from @ChrisCheungMD and myself on EARLY-AF now available through ACC. https://t.co/MKlki75Y2D
RT @DrJasonAndrade: A brief review from @ChrisCheungMD and myself on EARLY-AF now available through ACC. https://t.co/MKlki75Y2D
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/uYyd1vS7Uq
RT @DrJasonAndrade: A brief review from @ChrisCheungMD and myself on EARLY-AF now available through ACC. https://t.co/MKlki75Y2D
RT @DrJasonAndrade: A brief review from @ChrisCheungMD and myself on EARLY-AF now available through ACC. https://t.co/MKlki75Y2D
A brief review from @ChrisCheungMD and myself on EARLY-AF now available through ACC. https://t.co/MKlki75Y2D https://t.co/Gr7sfYVYRu
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/eNqXlKb2hD
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. https://t.co/iCxSgWFGjx
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/qsMUD9jrBn
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/RZiLOMpUyb
6/ Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation @DrJasonAndrade https://t.co/wjqv3TYlFM Jason G Andrade
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/3tZqpICkR9
クライオバルーンアブレーションによる心房細動治療は薬物治療に比べ上室性頻拍の抑制効果が得られたとの報告。 心房細動があると離床や運動で結構厄介なので選択肢増えるのありがたい。 Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/3xRZck386b
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/rIM6xzZTZV
RT @ernestocardio: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/TXUlnaEwlZ @mencardio @tor…
RT @ernestocardio: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/TXUlnaEwlZ @mencardio @tor…
Cryoablation or drug therapy for initial treatment of atrial fibrillation https://t.co/7KVT8N9ZSk #pharmacists #pharmacy #health #healthcare
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/qsMUD9jrBn
RT @LFairclo: Congratulations to Dr. Umjeet Jolly and @StMarysGenHosp Regional Cardiac program team for contributing to this important newl…
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/js76w0ymp4
RT @ernestocardio: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/TXUlnaEwlZ @mencardio @tor…
RT @CCI_CIC: Impressive results presented at #AHA20 and simultaneously published in @NEJM! EARLY-AF is the largest trial comparing first-li…
RT @CCI_CIC: Impressive results presented at #AHA20 and simultaneously published in @NEJM! EARLY-AF is the largest trial comparing first-li…
RT @ernestocardio: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/TXUlnaEwlZ @mencardio @tor…
RT @ernestocardio: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/TXUlnaEwlZ @mencardio @tor…
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/erfGvOdkq6
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/32E76DxFvo
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/TXUlnaEwlZ @mencardio @torresviera @jstragazue @igormorr @drjarayg @recetario1 @Lguevaramath @DrPontecarlosi @emartinezgmg @shemybenchetrit @gonzaeperez @jpcostabel @GARCIAEDINSON95
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation https://t.co/csCDqC25Ct via @DrJasonAndrade & @atulverma_md et al
RT @CCI_CIC: Impressive results presented at #AHA20 and simultaneously published in @NEJM! EARLY-AF is the largest trial comparing first-li…
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/w8E6kDd1IK
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/C7FhrNGHji
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM https://t.co/61ZV2xosmW
RT @CCI_CIC: Impressive results presented at #AHA20 and simultaneously published in @NEJM! EARLY-AF is the largest trial comparing first-li…
RT @CCI_CIC: Impressive results presented at #AHA20 and simultaneously published in @NEJM! EARLY-AF is the largest trial comparing first-li…
Impressive results presented at #AHA20 and simultaneously published in @NEJM! EARLY-AF is the largest trial comparing first-line ablation to anti-arrhythmic drugs for #AFib rhythm control. Congratulations to CCI Investigator @DrJasonAndrade & team! https://t.co/VBqHgVZzS4 #EPeeps https://t.co/puxTIZJK8u